Satellite Symposium | Patient with R/R CLL—Latin American perspective

The virtual Lymphoma Hub Satellite Symposium, at the European School of Haematology (ESH) ‘2nd How to Diagnose and Treat: Lymphoma’ conference, saw a panel of international experts come together to discuss how to manage patients with relapsed and/or refractory (R/R) lymphoma. Professor Astrid Pavlovsky, Fundaleu, Buenos Aires, AR, discussed how she would treat a patient with chronic lymphocytic leukemia (CLL) who has relapsed after treatment with venetoclax + rituximab.

Professor Astrid Pavlovsky begins with an overview of the prevalence of common B-cell non-Hodgkin lymphoma types in Central and South America. She then highlights the lack of targeted therapies and diagnostic techniques in some Latin American countries.

Astrid Pavlovsky recommends therapeutic intervention with a Bruton’s tyrosine kinase (BTK) inhibitor, and presented data from the ELEVATE CLL R/R study, which compared ibrutinib versus acalabrutinib for the treatment of high-risk CLL.